leflunomide has been researched along with Fibrosis in 8 studies
Leflunomide: An isoxazole derivative that inhibits dihydroorotate dehydrogenase, the fourth enzyme in the pyrimidine biosynthetic pathway. It is used an immunosuppressive agent in the treatment of RHEUMATOID ARTHRITIS and PSORIATIC ARTHRITIS.
leflunomide : A monocarboxylic acid amide obtained by formal condensation of the carboxy group of 5-methyl-1,2-oxazole-4-carboxylic acid with the anilino group of 4-(trifluoromethyl)aniline. The prodrug of teriflunomide.
Fibrosis: Any pathological condition where fibrous connective tissue invades any organ, usually as a consequence of inflammation or other injury.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Omeprazole does not inhibit Th2 cytokine-stimulated eotaxin-3 expression by esophageal fibroblasts, suggesting that PPIs will have limited impact on subepithelial EoE processes such as fibrosis." | 3.83 | JAK-STAT6 Pathway Inhibitors Block Eotaxin-3 Secretion by Epithelial Cells and Fibroblasts from Esophageal Eosinophilia Patients: Promising Agents to Improve Inflammation and Prevent Fibrosis in EoE. ( Cheng, E; Huo, X; Park, JY; Souza, RF; Spechler, SJ; Wang, DH; Wilson, KS; Yu, C; Zhang, Q; Zhang, X, 2016) |
| "Leflunomide can decrease the deposit of immunocomplex, down regulate the expression of TGF-beta1, MCP-1 in kidney, diminish local inflammatory reaction, relieve hyperplasia of mesangial matrix, related the process of nephrotic fibrosis, and protect renal function." | 3.74 | [Study on protective effects and its mechanism of leflunomide on renal tissue in rat IgA nephropathy model]. ( Liu, X; Lou, TQ; Peng, H; Tang, H; Tang, Y; Wang, C, 2008) |
| "Primary IgA nephropathy (IgAN) and HSPN share common features; thus, the Oxford classification of IgAN might be useful in predicting the long-term outcomes of HSPN." | 1.48 | Value of the Oxford classification of IgA nephropathy in children with Henoch-Schönlein purpura nephritis. ( Ding, J; Li, Y; Su, B; Wang, F; Wang, S; Xiao, H; Xu, K; Zhang, L; Zhong, X, 2018) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (12.50) | 18.2507 |
| 2000's | 1 (12.50) | 29.6817 |
| 2010's | 5 (62.50) | 24.3611 |
| 2020's | 1 (12.50) | 2.80 |
| Authors | Studies |
|---|---|
| Dai, X | 1 |
| Sun, Y | 1 |
| Ma, L | 2 |
| Hou, J | 1 |
| Wang, L | 1 |
| Gong, Y | 1 |
| Sun, X | 1 |
| Wu, S | 1 |
| Wang, J | 1 |
| Ji, Z | 1 |
| Chen, H | 1 |
| Jiang, L | 1 |
| Kong, X | 1 |
| Morin, F | 1 |
| Kavian, N | 1 |
| Chouzenoux, S | 1 |
| Cerles, O | 1 |
| Nicco, C | 1 |
| Chéreau, C | 1 |
| Batteux, F | 1 |
| Xu, K | 1 |
| Zhang, L | 1 |
| Ding, J | 1 |
| Wang, S | 1 |
| Su, B | 1 |
| Xiao, H | 1 |
| Wang, F | 1 |
| Zhong, X | 1 |
| Li, Y | 1 |
| Ma, ZG | 1 |
| Zhang, X | 2 |
| Yuan, YP | 1 |
| Jin, YG | 1 |
| Li, N | 1 |
| Kong, CY | 1 |
| Song, P | 1 |
| Tang, QZ | 1 |
| Pescatore, LA | 1 |
| Laurindo, FRM | 1 |
| Cheng, E | 1 |
| Wilson, KS | 1 |
| Wang, DH | 1 |
| Park, JY | 1 |
| Huo, X | 1 |
| Yu, C | 1 |
| Zhang, Q | 1 |
| Spechler, SJ | 1 |
| Souza, RF | 1 |
| Tang, Y | 1 |
| Lou, TQ | 1 |
| Wang, C | 1 |
| Peng, H | 1 |
| Liu, X | 1 |
| Tang, H | 1 |
| Stosic-Grujicic, S | 1 |
| Dimitrijevic, M | 1 |
| Bartlett, RR | 1 |
8 other studies available for leflunomide and Fibrosis
| Article | Year |
|---|---|
A novel molecular mechanism of vascular fibrosis in Takayasu arteritis: macrophage-derived GPNMB promoting adventitial fibroblast extracellular matrix production in the aorta.
Topics: Adventitia; Aorta; Extracellular Matrix; Fibroblasts; Fibrosis; Humans; Leflunomide; Macrophages; Me | 2023 |
Leflunomide prevents ROS-induced systemic fibrosis in mice.
Topics: Animals; Antirheumatic Agents; Autoantibodies; Bleomycin; Cells, Cultured; Disease Models, Animal; F | 2017 |
Value of the Oxford classification of IgA nephropathy in children with Henoch-Schönlein purpura nephritis.
Topics: Adolescent; Anti-Inflammatory Agents; Antibiotics, Antineoplastic; Atrophy; Biopsy; Child; Child, Pr | 2018 |
A77 1726 (leflunomide) blocks and reverses cardiac hypertrophy and fibrosis in mice.
Topics: Animals; Cell Differentiation; Cells, Cultured; Disease Models, Animal; Fibroblasts; Fibrosis; Heart | 2018 |
Leflunomide counter
Topics: Angiotensin II; Aniline Compounds; Animals; Cardiomegaly; Crotonates; Fibrosis; Hydroxybutyrates; Le | 2018 |
JAK-STAT6 Pathway Inhibitors Block Eotaxin-3 Secretion by Epithelial Cells and Fibroblasts from Esophageal Eosinophilia Patients: Promising Agents to Improve Inflammation and Prevent Fibrosis in EoE.
Topics: Cell Line, Transformed; Chemokine CCL26; Chemokines, CC; Eosinophilic Esophagitis; Eosinophils; Epit | 2016 |
[Study on protective effects and its mechanism of leflunomide on renal tissue in rat IgA nephropathy model].
Topics: Animals; Chemokine CCL2; Disease Models, Animal; Fibrosis; Glomerulonephritis, IGA; Isoxazoles; Kidn | 2008 |
Prevention of experimental autoimmune diabetes in mice by treatment with leflunomide.
Topics: Aniline Compounds; Animals; Crotonates; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; | 1998 |